Data standards for acute coronary syndrome and percutaneous coronary intervention: the European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart) — Gorav Batra (2022) | RDL Network
Data standards for acute coronary syndrome and percutaneous coronary intervention: the European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart)
Article 2022 en
Authors
GB
Gorav Batra
SA
Suleman Aktaa
LW
Lars Wallentin
Abstract
1 min read
Standardized data definitions are essential for monitoring and benchmarking the quality of care and patient outcomes in observational studies and randomized controlled trials. There are no contemporary pan-European data standards for the acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI). The European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart) project of the European Society of Cardiology (ESC) aimed to develop such data standards for ACS and PCI. Following a systematic review of the literature on ACS and PCI data standards and evaluation of contemporary ACS and PCI registries, we undertook a modified Delphi process involving clinical and registry experts from 11 European countries, as well as representatives from relevant ESC Associations, including the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and Acute CardioVascular Care (ACVC). This resulted in final sets of 68 and 84 'mandatory' variables and several catalogues of optional variables for ACS and PCI, respectively. Data definitions were provided for these variables, which have been programmed as the basis for continuous registration of individual patient data in the online EuroHeart IT platform. By means of a structured process and the interaction with major stakeholders, internationally harmonized data standards for ACS and PCI have been developed. In the context of the EuroHeart project, this will facilitate country-level quality of care improvement, international observational research, registry-based randomized trials, and post-marketing surveillance of devices and pharmacotherapies.
Suleman Aktaa, Gorav Batra, John G.F. Cleland, Andrew J.S. Coats, Lars H. Lund, Theresa A. McDonagh, Giuseppe Rosano, Petar Seferović, Peter Vaško, Lars Wallentin, Aldo Maggioni, Barbara Casadei, Chris P Gale
Asad Bhatty, Chris Wilkinson, Gorav Batra, Joakim Alfredsson, David Erlinge, Jorge Ferreira, Ingibjörg Guđmundsdóttir, Þórdís Jóna Hrafnkelsdóttir, Inga Jóna Ingimarsdóttir, Alar Irs, Zoltán Járai, András Jánosi, Bogdan A. Popescu, Manuel A. S. Santos, Peter Vaško, Dragoş Vinereanu, Jonathan Yap, Aldo Maggioni, Lars Wallentin, Barabara Casadei, Chris P Gale
Suleman Aktaa, Gorav Batra, Stefan James, Daniel J. Blackman, Peter Ludman, Mamas A. Mamas, Mohamed Abdel‐Wahab, Gianni D. Angelini, Martin Czerny, Victoria Delgado, Giuseppe De Luca, Eustachio Agricola, Dan Foldager, Christian W. Hamm, Bernard Iung, Norman Mangner, Julinda Mehilli, Gavin J. Murphy, Darren Mylotte, Radosław Parma, Anna Sonia Petronio, Bodgan A Popescu, Lars Søndergaard,
Gorav Batra, Suleman Aktaa, A. John Camm, Francisco Moscoso Costa, Luigi Di Biase, David Duncker, Laurent Fauchier, Nikolaos Fragakis, Lars Frost, Ziad Hijazi, Tord Juhlin, José Luís Merino, Lluı́s Mont, Jens Cosedis Nielsen, Jonas Oldgren, Anna Polewczyk, Tatjana Potpara, Frédéric Sacher, Philipp Sommer, Roland Richard Tilz, Aldo Maggioni, Lars Wallentin,
Discussion(0)
No comments yet. Be the first to comment.